TerminatedPhase 4

RAPID-2. A Study to Evaluate the Effectiveness of Alternate Dosing of PROCRIT (Epoetin Alfa) in Maintaining Hemoglobin Levels in Patients With Chemotherapy Related Anemia

Stopped: This study was stopped due to slow enrollment after enrolling 25 of 200 patients.

25 participantsStarted 2002-11

Plain-language summary

The purpose of this study was to determine if alternate dosing of Epoetin alfa was effective in maintaining hemoglobin levels in patients with chemotherapy related anemia.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Patients with chemotherapy related anemia * Patients with a diagnosis of malignancy * Patients with initial weekly PROCRIT (Epoetin alfa) therapy for at least 4 weeks * Patients must have received PROCRIT (Epoetin alfa) maintenance therapy with less frequent dosing (e.g. every 2 weeks, every 3 weeks, every 4 weeks) for at least 6 weeks immediately following once weekly dosing. Exclusion Criteria: * No previous diagnosis of hemolytic anemia or myelodysplasia

What they're measuring

Frequency and percentage of subjects in each dosing regimen will be summarized. Hemoglobin (Hb) response and maintenance of initial treatment phase Hb with alternate doses of Epoetin alfa. Time and reasons for discontinuing Epoetin alfa.

Trial details

NCT IDNCT00495378

SponsorOrtho Biotech Products, L.P.

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

View on ClinicalTrials.gov More Chemotherapy trials